Although no precise definition for rapidly progressive dementia (RPD) exists, this term is generally used to refer to cases with significant and progressive cognitive impairment that occurs over weeks or months. RPD represents an unusual but severe condition that causes distress not only for patients and their relatives but also for the clinicians involved, as multiple investigations and decisions about management must be made urgently to avoid misdiagnosing a treatable condition and to preserve as much of the neural tissue as possible from definite damage. While Creutzfeldt-Jacob disease (CJD) has for a long period of time been regarded as the prototype of RPD, this infrequent but severe condition can be produced by an extensive variety of causes such as various endocrine, metabolic or toxic disorders, central nervous system (CNS) infections, primary or secondary CNS neoplasms, various CNS vasculitides and various autoimmune conditions in which autoantibodies against neural tissue are produced, whether in the presence of a neoplasm or not. However, even in the more common and usually slowly progressive dementias such as Alzheimer's disease, frontotemporal lobar degeneration, dementia with Lewy bodies and other degenerative dementias, as well as vascular dementia, establishment and progression of the disease is occasionally surprisingly accelerated, leading to a clinical presentation of RPD. The few published case series of RPD have shown that the relative frequency of underlying diseases depends mainly on the clinical setting. Thus, CJD has been found to be the most prevalent cause in referral centres for spongiform encephalopathies, while secondary causes are more prevalent in general referral centres for dementia diagnosis. In clinical practice, for the cases presenting with RPD, the diagnostic procedure must be exhaustive, starting with a detailed clinical evaluation and proceeding to a complete laboratory work-up and sophisticated neuroimaging studies. There has been recent enormous progress in imaging, with sensitive new sequences of magnetic resonance imaging and immunology; as a result, a plethora of antibodies against the CNS can now be detected in cases of autoimmune dementias, which has dramatically changed the diagnostic approach and early management of cases of RPD. The same favourable effect in clinical practice comes from the accumulated knowledge of the complex clinical picture of various causes of RPD, associated specific neurological features (pyramidal signs, ataxia, myoclonus) and systematic features (weight loss, hyponatraemia, hepatic disorders) and their mode of progression.
The evaluation of behavioural alterations and neuropsychiatric symptoms is of high importance, since the initial symptoms can be exclusively a depressive-like or a disinhibited behaviour. Associated signs and symptoms, either neurological or systematic, can unveil an undetermined underlying disease. Ataxia, parkinsonism and specific motor or sensory deficits might herald the clinical expression of an otherwise obscure disorder during the progression of various forms of RPD.
Further investigation comprises laboratory testing, which includes routine serological studies (blood cell count, electrolyte levels, liver and renal function assessment, erythrocyte sedimentation rate and C-reactive protein, thyroid function evaluation including antithyroid autoantibodies, vitamin B12, folic acid, basic rheumatological screening and testing for HIV) and urine analysis. Cerebrospinal fluid (CSF) analysis of cell count, glucose and protein level, immunoglobin G index and oligoclonal bands, 14-3-3 and τ-protein is also required. Brain magnetic resonance imaging (MRI), including fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted imaging (DWI) sequences, is required for the diagnosis as in many instances it can be highly indicative of the underlying disorder (e.g. CJD and autoimmune encephalopathies).
The electroencephalogram (EEG) can also be helpful, albeit inconsistently, as a number of EEG findings (such as the periodic triphasic discharges observed in CJD) have relatively high specificity for certain disorders. 4, 6 A high proportion of RPD patients undergoing the routine assessments mentioned above will presumably receive a diagnosis during the initial stages of the investigations. However, the remaining cases might require additional serological or imaging testing. Given the rapid progression of the disease, there is high risk in restricting the initial evaluation. In most cases, it might appear rational to run investigations in parallel from the very beginning so as not to miss the early stages of a potentially treatable cause, as an important proportion of people with RPD disorders may benefit from therapy but only if treated before permanent neurological deficits are established. 2 
Neurodegenerative Disorders with a Rapid Course
A number of neurodegenerative diseases that usually progress gradually can also present as RPD. AD is the most common cause of dementia. The brains of affected patients exhibit hippocampal and temporoparietal cortical atrophy and the most common histological findings are senile plaques and neurofibrillary tangles. The median survival of AD patients is approximately 12 years, but occasionally the deterioration course can be rapid, mimicking CJD, especially when combined with amyloid angiopathy. Although CJD is the most frequent cause of RPD, 8 AD represents a major non-CJD cause and in our centre was the third most common cause. 3 However, AD was much less common in the University of California, San Francisco series, which came from a major prion disease referral centre. Rapidly Progressing Dementia -Clinical Aspects and Management Frontotemporal lobar degeneration (FTLD) occurs earlier in life than AD. In our centre, 3 FTLD was the third most common cause of RPD, accounting for 16.2 % of the studied cases, and FTLD was also among the most common non-CJD causes of RPD in the UCSF study. Other tau-related pathologies, such as corticobasal degeneration (see Figure 1) and progressive supranuclear palsy, may progress as RPD and have been marked as potent causes of rapid cognitive decline by many studies. [1] [2] [3] The motor symptoms associated with these pathologies, including myoclonus and parkinsonism, can easily be misdiagnosed as CJD. In any case, given the fact that any neurodegenerative dementia can follow an accelerated course in the presence of an underlying infection, metabolic deregulation or drug toxicity (e.g. benzodiazepines), such disorders should be thoroughly ruled out during clinical assessment.
Creutzfeldt-Jakob Disease
Spongiform encephalopathy (CJD) is caused by the transformation of the normal neuronal prion protein, resulting in its abnormal accumulation within the neurons. The disease can have a sporadic form (sCJD), a familial/genetic form and a variant form (vCJD).
sCJD, which is the most common form of all -accounting for approximately 85 % of cases -is still a rare disease affecting 1-1.5 people/million/year. 21 The clinical presentation of sCJD is characterised by an extremely variable picture of cognitive disturbances (attentional deficits, amnesia, aphasia, apraxia)
that lead rapidly to dementia (in weeks or months), cerebellar ataxia, extrapyramidal symptoms, myoclonus and multiple behavioural/psychiatric disturbances (hallucinations, delusions, misidentifications, anxiety, aggression, etc.). 22 Posterior cortical symptoms -such as cortical blindness, palinopsia, gaze apraxia and optic ataxia -are also commonly found and, when encountered at disease onset, characterise the Heidenhain variant of the disease. 23 sCJD usually occurs at 50-70 years of age and affects both sexes equally. 1 Survival is very short and 85 % of patients are dead by the end of the first year after onset. 1 Genetic forms of CJD are attributable to various mutations of the prion protein gene and include familial CJD, Gerstmann-Sträussler-Scheinker and fatal familial insomnia.
Genetic forms of CJD tend to have a slower course, although they often have the same clinical presentation as sCJD. 24 More than half of genetic cases do not have a known family history of CJD. 25 Initially, focal or diffuse slowing is seen on the EEG but, with disease progression, pseudo-periodic and, eventually, periodic 1-2 Hz triphasic sharp waves appear. Although this periodic EEG pattern is highly characteristic of sCJD, it takes its typical form only in the late stages of the disease and not in all patients. 26, 27 In addition, the same EEG findings can be encountered in various other disorders, mainly of toxic or metabolic cause (e.g. lithium encephalopathy) or in herpetic encephalitis. CSF protein level can be mildly increased and oligoclonal bands may be present. 28 By contrast, cell count is always normal.
Several CSF protein levels, mainly 14-3-3, neuron-specific enolase and τ-protein, have been shown to be increased in CJD, 28, 29 and thus have been proposed as diagnostic markers for this disease. However, the use of these markers has been criticised as they lack sensitivity and specificity, especially in the initial stages of the disease. 21, 29 Novel MRI techniques have altered the diagnostic approach in CJD to a considerable degree. Early in the disease course, FLAIR and DWI sequences demonstrate hypersignals in the striatum (caudate and putamen) and thalamus as well as 'cortical ribboning' (hypersignal delineating the cortex) in the parietal, temporal and frontal cortices (see Figure 2) . MRI with these sequences (DWI being more sensitive Rapidly Progressing Dementia -Clinical Aspects and Management 
Metabolic/Toxic Causes of Rapidly Progressive Dementia
Although rare, inherited metabolic disorders should also be taken into account during the assessment of RPD, especially in younger patients. 6 Adult-onset leukodystrophies usually initiate with cognitive decline, psychiatric symptoms, ataxia, dystonia and progressive gait disturbance. 46 
Vascular Dementias
Vascular disorders are a rather uncommon cause of RPD. 1, 3 Multi-infarct dementia is the result of numerous diffuse minor strokes that eventually lead to memory and executive function impairment.
On the other hand, isolated strategic infarcts in the thalamus anterior corpus callosum and the striatum may lead to rapid cognitive decline as well. 50 
Normal Pressure Hydrocephalus
Normal pressure hydrocephalus is an important, and reversible, secondary causative factor of dementia which can take the form of an RPD. 3 The clinical spectrum of normal pressure hydrocephalus involves the classic triad of memory impairment, gait disorders and urinary incontinence. Brain MRI will reveal enlargement of the ventricular system. Diagnosis can be confirmed by means of CSF pressure measurement.
Psychiatric Causes of Rapidly Progressive Dementia
Following the exclusion of all neurological and systemic causes of RPD, the possibility of pseudodementia should be considered.
Patients with a history of major depression may exhibit symptoms of rapid cognitive decline. Although apathy and other depressive symptoms might prevail, this situation can mimic RPD and the differential diagnosis is often difficult.
Autoimmune Dementias
Although autoimmune encephalopathies were thought to be rare in the past, it appears that they represent a relatively frequent cause of RPD. non-specific findings such as white matter hyperintense lesions (see Figure 4 ).
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The EEG will show non-specific slowing and occasionally epileptiform discharges suggestive of CJD. 65 Hashimoto encephalopathy responds well to corticosteroid treatment, which can be prolonged to achieve a full remission.
Other Autoimmune Conditions
Systemic 
